#USA #Dallas #thrombectomy #Vesalio #Greg Cook

Vesalio Welcomes Greg Cook as Chief Commercial Officer

In a significant development for the future of vascular intervention, Vesalio, a prominent player in this sector, has appointed Greg Cook as its new Chief Commercial Officer (CCO). Cook will be at the forefront of driving Vesalio's commercial strategy, focusing on expansion across their increasingly sophisticated thrombectomy technologies.

A Leader in Medical Device Commercialization

Greg Cook comes to Vesalio with over 20 years of experience in the medical device industry. Before his current role, he served as Senior Vice President of Sales at Philips Image Guided Therapy Devices, where he was instrumental in the successful commercialization of the VeriSight™ intracardiac echocardiography platform. His track record also includes leading Philips' Cardiac Lead Management sales operations, where he honed his ability to foster relationships with physicians and navigate the complexities of market development.

Cook's expertise is set to be an invaluable asset as Vesalio embarks on an ambitious path of expanding its thrombectomy platform to serve neurovascular, coronary, and peripheral vascular markets. Through partnerships with healthcare professionals and stakeholders, Cook aims to enhance the adoption of Vesalio's innovative technologies aimed at improving patient outcomes.

Strategic Vision for Commercial Expansion

In his new role, Cook has expressed enthusiasm for joining Vesalio and contributing to their mission of advancing thrombectomy management. “Vesalio’s commitment to clinical innovation and partnerships with physicians creates a strong base for ongoing growth,” Cook said. He is determined to broaden access to the technologies crucial for improving clinical outcomes in patients suffering from thromboembolic vascular diseases.

CEO Steve Rybka remarked on Cook's appointment, emphasizing the strategic alignment of his experience with Vesalio's goals. Rybka noted, “Greg brings the commercial leadership, market development expertise, and physician relationships that align with Vesalio's strategic priorities.” This assertion reinforces confidence in Cook’s ability to facilitate Vesalio's growth trajectory in a competitive landscape.

About Vesalio and Its Innovative Solutions

Vesalio is dedicated to enhancing patient care for those afflicted with thromboembolic vascular disease. Their proprietary technology, including the NeVa®, enVast™, and pVasc® platforms, have been developed to efficiently remove clots and restore blood flow in critical areas such as the brain, heart, and peripheral regions. With a history of treating more than 19,000 patients across over 60 countries, Vesalio seeks to lead the charge in advancing clinical solutions and improving healthcare outcomes globally.

In conclusion, with Greg Cook at the helm of their commercial strategies, Vesalio is poised to strengthen its position in the vascular intervention market significantly. The company’s focus on continuous innovation and collaboration with healthcare professionals underscores its ongoing commitment to enhancing patient care in critical health scenarios.